Aceso Life Science Group Limited disclosed a Next Day Disclosure Return showing an increase in its total issued shares through a consideration issue under a general mandate. The company’s issued shares rose from 7.38 billion to 8.86 billion as of 03 March 2026, representing an issuance of approximately 1.48 billion new shares (about 20.00% of the existing share capital). The issue price for these consideration shares is HKD 0.12 per share.

According to the disclosure, these newly issued shares follow a subscription agreement dated 30 January 2026 and have been duly authorized by the board. The closing balance of issued shares now stands at 8.86 billion. All applicable regulatory requirements and listing rules for this allotment have been confirmed as fulfilled.